Atrial Fibrillation – Pipeline Review, H2 2017

Global Markets Direct’s, ‘Atrial Fibrillation – Pipeline Review, H2 2017’, provides an overview of the Atrial Fibrillation pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Atrial Fibrillation, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Atrial Fibrillation and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Atrial Fibrillation

The report reviews pipeline therapeutics for Atrial Fibrillation by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Atrial Fibrillation therapeutics and enlists all their major and minor projects

The report assesses Atrial Fibrillation therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Atrial Fibrillation

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Atrial Fibrillation

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Atrial Fibrillation pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Acesion Pharma Aps

ARCA biopharma Inc

Armetheon Inc

AstraZeneca Plc

Bristol-Myers Squibb Company

Cardiome Pharma Corp

Daiichi Sankyo Company Ltd

Dong-A Socio Holdings Co Ltd

Gilead Sciences Inc

InCarda Therapeutics Inc

Merck & Co Inc

N-Gene Research Laboratories Inc

Nissan Chemical Industries Ltd

OMEICOS Therapeutics GmbH

Verseon Corp

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

Introduction 5

Global Markets Direct Report Coverage 5

Atrial Fibrillation - Overview 6

Atrial Fibrillation - Therapeutics Development 7

Pipeline Overview 7

Pipeline by Companies 8

Pipeline by Universities/Institutes 9

Products under Development by Companies 10

Products under Development by Universities/Institutes 11

Atrial Fibrillation - Therapeutics Assessment 12

Assessment by Target 12

Assessment by Mechanism of Action 14

Assessment by Route of Administration 16

Assessment by Molecule Type 18

Atrial Fibrillation - Companies Involved in Therapeutics Development 20

Acesion Pharma Aps 20

ARCA biopharma Inc 20

Armetheon Inc 21

AstraZeneca Plc 21

Bristol-Myers Squibb Company 22

Cardiome Pharma Corp 22

Daiichi Sankyo Company Ltd 23

Dong-A Socio Holdings Co Ltd 23

Gilead Sciences Inc 24

InCarda Therapeutics Inc 24

Merck & Co Inc 25

N-Gene Research Laboratories Inc 25

Nissan Chemical Industries Ltd 26

OMEICOS Therapeutics GmbH 26

Verseon Corp 27

Atrial Fibrillation - Drug Profiles 28

AFC-1 - Drug Profile 28

BGP-15 - Drug Profile 29

BMS-919373 - Drug Profile 31

bucindolol hydrochloride - Drug Profile 32

budiodarone - Drug Profile 39

edoxaban tosylate - Drug Profile 41

flecainide acetate - Drug Profile 47

GBCA-1 - Drug Profile 49

Gene Therapy for Atrial Fibrillation - Drug Profile 50

GS-967 - Drug Profile 51

Heparin - Drug Profile 52

MK-1832 - Drug Profile 53

NIP-151 - Drug Profile 54

NYK-1112 - Drug Profile 56

OMT-28 - Drug Profile 57

Small Molecule to Block Calcium Activated Potassium Channel for Atrial Fibrillation - Drug Profile 58

Small Molecule to Block Kv1.5 for Atrial Fibrillation - Drug Profile 59

Small Molecules to Block GIRK for Atrial Fibrillation - Drug Profile 60

Small Molecules to Inhibit CaMKII for Arrhythmias and Heart Failure - Drug Profile 61

Small Molecules to Inhibit Thrombin for Cardiovascular Diseases - Drug Profile 62

vernakalant hydrochloride - Drug Profile 64

Atrial Fibrillation - Dormant Projects 69

Atrial Fibrillation - Discontinued Products 72

Atrial Fibrillation - Product Development Milestones 74

Featured News & Press Releases 74

Appendix 85

Methodology 85

Coverage 85

Secondary Research 85

Primary Research 85

Expert Panel Validation 85

Contact Us 85

Disclaimer 86

List of Tables

List of Tables

Number of Products under Development for Atrial Fibrillation, H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products under Development by Universities/Institutes, H2 2017

Products under Development by Companies, H2 2017

Products under Development by Universities/Institutes, H2 2017

Number of Products by Stage and Target, H2 2017

Number of Products by Stage and Mechanism of Action, H2 2017

Number of Products by Stage and Route of Administration, H2 2017

Number of Products by Stage and Molecule Type, H2 2017

Atrial Fibrillation – Pipeline by Acesion Pharma Aps, H2 2017

Atrial Fibrillation – Pipeline by ARCA biopharma Inc, H2 2017

Atrial Fibrillation – Pipeline by Armetheon Inc, H2 2017

Atrial Fibrillation – Pipeline by AstraZeneca Plc, H2 2017

Atrial Fibrillation – Pipeline by Bristol-Myers Squibb Company, H2 2017

Atrial Fibrillation – Pipeline by Cardiome Pharma Corp, H2 2017

Atrial Fibrillation – Pipeline by Daiichi Sankyo Company Ltd, H2 2017

Atrial Fibrillation – Pipeline by Dong-A Socio Holdings Co Ltd, H2 2017

Atrial Fibrillation – Pipeline by Gilead Sciences Inc, H2 2017

Atrial Fibrillation – Pipeline by InCarda Therapeutics Inc, H2 2017

Atrial Fibrillation – Pipeline by Merck & Co Inc, H2 2017

Atrial Fibrillation – Pipeline by N-Gene Research Laboratories Inc, H2 2017

Atrial Fibrillation – Pipeline by Nissan Chemical Industries Ltd, H2 2017

Atrial Fibrillation – Pipeline by OMEICOS Therapeutics GmbH, H2 2017

Atrial Fibrillation – Pipeline by Verseon Corp, H2 2017

Atrial Fibrillation – Dormant Projects, H2 2017

Atrial Fibrillation – Dormant Projects, H2 2017 (Contd..1), H2 2017

Atrial Fibrillation – Dormant Projects, H2 2017 (Contd..2), H2 2017

Atrial Fibrillation – Discontinued Products, H2 2017

Atrial Fibrillation – Discontinued Products, H2 2017 (Contd..1), H2 2017

List of Figures

List of Figures

Number of Products under Development for Atrial Fibrillation, H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products under Development by Universities/Institutes, H2 2017

Number of Products by Top 10 Targets, H2 2017

Number of Products by Stage and Top 10 Targets, H2 2017

Number of Products by Top 10 Mechanism of Actions, H2 2017

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017

Number of Products by Routes of Administration, H2 2017

Number of Products by Stage and Routes of Administration, H2 2017

Number of Products by Molecule Types, H2 2017

Number of Products by Stage and Molecule Types, H2 2017

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports